Top of this page
Skip navigation, go straight to the content Newsroom UCB U.S. News


  • Press Release: UCB Presents New Data Demonstrating Commitment to Epilepsy at 2019 American Epilepsy Society Meeting

    • 14 scientific presentations will cover UCB’s pipeline assets, epilepsy-specific research, and licensed medicines, including NAYZILAM, now available for the acute treatment of seizure clusters in epilepsy patients 12 years of age and older
    • Friday evening symposium on “Epilepsy Treatment Update for Patients Suffering from Seizure Clusters” includes Epilepsy Foundation’s project on seizure emergencies and a panel discussion on the misconceptions around seizure clusters

    Read more

  • Like
  • Press Release: UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients


    • BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
    • Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
    • Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,1, 2
    • Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.

    Read more

  • Like